Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Bridging-BiTE
- Development stage
- Preclinical
- Lead developer
- Ehime University
- Modality
- T-cell Engagers → Multispecific Antibodies → Engineered Antibody Formats → Antibody-Based Therapeutics, Bispecific Antibodies → Multispecific Antibodies → Engineered Antibody Formats → Antibody-Based Therapeutics, Antibody Fragments → Engineered Antibody Formats → Antibody-Based Therapeutics
- Administration
- Intravenous
01
Overview
Bridging-BiTE (B-BiTE) is a novel bispecific T-cell engager (BiTE) modality developed by researchers at Ehime University for the treatment of multiple myeloma and other refractory hematological malignancies. B-BiTE is designed as a bispecific molecule containing two single-chain variable fragments (scFvs): one specific for the Fc domain of human immunoglobulin G (IgG) and the other specific for the CD3ε subunit of the T-cell receptor complex. When mixed with clinically available monoclonal antibodies (mAbs) such as daratumumab or elotuzumab, B-BiTE binds to the mAb's Fc region to form a mAb/B-BiTE complex. This complex redirects T-cell cytotoxicity against tumor cells via CD3ε binding while preserving and supporting natural killer (NK) cell reactivity through the mAb's Fc region, resulting in dual-lymphoid activation and enhanced anti-tumor efficacy.
- Other names
- B-BiTEBridging-Bispecific T-cell Engager
02
Targets
IgG Fc (Immunoglobulin G Fc region)CD3 (T-cell surface glycoprotein CD3)
Beyond the preview
Go deeper on Bridging-BiTE.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Bridging-BiTE.